Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children.

Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A.

Clinicoecon Outcomes Res. 2014 Apr 8;6:187-96. doi: 10.2147/CEOR.S44079. eCollection 2014.

2.

Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis.

Rønborg SM, Svendsen UG, Micheelsen JS, Ytte L, Andreasen JN, Ehlers L.

Clinicoecon Outcomes Res. 2012;4:253-60. doi: 10.2147/CEOR.S34832. Epub 2012 Sep 11.

3.

Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.

Nelson H, Lehmann L, Blaiss MS.

Curr Med Res Opin. 2012 Jun;28(6):1043-51. doi: 10.1185/03007995.2012.684676. Epub 2012 May 9. Review.

PMID:
22502864
4.

Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.

Senna GE, Calderon M, Milani M.

Expert Rev Clin Immunol. 2011 Jan;7(1):21-7. doi: 10.1586/eci.10.89.

PMID:
21162646
5.

Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life.

Frølund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, Dahl R.

Allergy. 2010 Jun 1;65(6):753-7. doi: 10.1111/j.1398-9995.2009.02238.x. Epub 2009 Nov 2.

7.

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB.

Clin Exp Allergy. 2007 May;37(5):772-9.

PMID:
17456225
8.

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study.

Reiber R, Keller M, Keller W, Wolf H, Schnitker J, Wüstenberg E.

Clin Transl Allergy. 2016 Mar 8;6:9. doi: 10.1186/s13601-016-0097-8. eCollection 2015.

9.

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.

Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB.

Allergy. 2008 Dec;63(12):1624-9. doi: 10.1111/j.1398-9995.2008.01743.x.

10.

Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.

Valovirta E, Berstad AK, de Blic J, Bufe A, Eng P, Halken S, Ojeda P, Roberts G, Tommerup L, Varga EM, Winnergard I; GAP investigators.

Clin Ther. 2011 Oct;33(10):1537-46. doi: 10.1016/j.clinthera.2011.09.013. Epub 2011 Oct 13.

PMID:
21999887
11.
12.

Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.

Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.

Clin Ther. 2011 Jul;33(7):828-40. doi: 10.1016/j.clinthera.2011.06.006. Epub 2011 Jul 7.

PMID:
21741092
13.

SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.

Dahl R, Roberts G, de Blic J, Canonica GW, Kleine-Tebbe J, Nolte H, Lawton S, Nelson HS.

Allergy Asthma Proc. 2016 Mar-Apr;37(2):92-104. doi: 10.2500/aap.2016.37.3937. Epub 2016 Jan 21.

PMID:
26802643
14.
15.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.

Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F.

J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7. doi: 10.1016/j.jaci.2008.10.044.

PMID:
19130937
16.

Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.

Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, Klink R; GAP investigators.

J Allergy Clin Immunol. 2017 Jul 6. pii: S0091-6749(17)31088-6. doi: 10.1016/j.jaci.2017.06.014. [Epub ahead of print]

17.
18.

[Economic evaluation of a tablet-based vaccination against hay fever in Denmark].

Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U.

Ugeskr Laeger. 2008 Jan 14;170(3):138-42. Danish.

PMID:
18208729
19.

Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany.

Westerhout KY, Verheggen BG, Schreder CH, Augustin M.

J Med Econ. 2012;15(5):906-17. doi: 10.3111/13696998.2012.688904. Epub 2012 May 24.

PMID:
22533527
20.

Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults.

Ruggeri M, Oradei M, Frati F, Puccinelli P, Romao C, Dell'Albani I, Incorvaia C, Cicchetti A.

Clin Drug Investig. 2013 May;33(5):343-9. doi: 10.1007/s40261-013-0067-z.

Supplemental Content

Support Center